Contact Us (781) 301-7474

Board of Directors

Learn about our Board of Directors and the experience that they bring to Hemanext.

Martin Cannon

President and CEO - Hemanext

MORE ⤑
Mr. Cannon has served as President, CEO and board member of Hemanext since 2004. Prior to joining Hemanext, Mr. Cannon held senior positions with several leading management consulting firms including 15 years at Bain & Company and A.T. Kearney, which in 1997 acquired Cannon Associates, an international consulting and business development firm founded by Mr. Cannon. As a partner at Bain & Company and with his firm Cannon Associates, Mr. Cannon consulted extensively on growth and innovation strategies in a variety of industries including diagnostic instrumentation, blood banking and hospital management. Mr. Cannon also served as Executive Vice President with Commerce One, Inc., and Group President, Management Consulting with AppNet, Inc. where he was responsible for the development and deployment of software-based decision support platforms. He has served as a Board Member of the National Symphony Orchestra, The Washington Chorus and The US Russia Business Council. He is a graduate of Oxford University.

Guy Cogan

Former Senior Partner at Monitor Deloitte

MORE ⤑

Guy Cogan is a Senior Partner at Monitor Deloitte and serves as the Global Leader for Strategy and Operations Consulting. Guy started his career at Bain & Company in London, England where he ultimately served as the Managing Partner of the UK operations. He has also held leadership positions at AT Kearney and Monitor Group, before its acquisition by Deloitte Consulting. With 30 years of industry and consulting experience, his work has included both accelerating growth and improving profitability at corporate and business unit levels for major global clients. Guy holds a BA and MA in Engineering from St Catharine’s College, Cambridge University, as well as an MBA from the Harvard Business School, where he was named a Baker Scholar.

Steve Eckert

Classic Communities Organization CEO

MORE ⤑
Stephen Eckert is President and CEO of Classic Communities Corporation (CCC). CCC is a privately held homebuilder and developer with projects across Maryland. Steve began his career in property development in 1978 as the Director of Government Relations for the Maryland National Capital Building Industry Association. He joined Herman Porten in 1980 to help assemble the property that served as the foundation for a new company, Porten Sullivan Corporation where he eventually became President. Steve left Porten Sullivan in 1989 to found CCC. Steve is the recipient of the Milton Kettler Award for lifetime contributions to the community at large and the homebuilding industry, having served on multiple special committees for the Montgomery County Council as well as serving as a frequent panelist at the annual Montgomery County Symposium on Affordable Housing. Steve has also served as President as well as a member of the Board of Directors and Executive Committee of the Maryland National Capital Building Industry Association. Steve received his Bachelor’s and Master’s degree in History from the University of Illinois.

Richard Perle

American Enterprise Institute Resident Fellow

MORE ⤑
Richard Perle is a Resident Fellow at the American Enterprise Institute (AEI). Previously he served as member of the Defense Policy Board from 1987 to 2004 and as its chairman from 2001 to 2003; assistant secretary of defense for international security policy (1981-1987), and a staff member to Senator Henry Jackson (D-Wash.) (1969-1980). Mr. Perle is coauthor of “An End to Evil” (Random House, 2003) and author of “Hard Line”, a political novel. He co-directed AEI’s Commission on Future Defenses. He earned a M.A. in political science from Princeton University and a B.A. from the University of Southern California.

David Testa

Former Vice Chairman and Chief Investment Officer, T. Rowe Price

MORE ⤑
Until his retirement in 2004, Mr. Testa was Vice Chairman and Chief Investment of T. Rowe Price where he built a very successful 30+ year career. Prior to joining T. Rowe Price, Mr. Testa worked for IBM in their Data Processing Division. He earned his undergraduate degree from Williams College and his MBA from Harvard Business School, where he was named a Baker Scholar.

Eduardo Avayú

Director and Owner of Empresas Indumotora SA

MORE ⤑
Mr. Eduardo Avayu is vice chairman of family owned Empresas Indumotora SA, which represents, wholesales, and distributes automobiles, trucks, and buses in Chile. Mr. Avayu was also on the board of Forum Financial Services, owned by the Avayu and Yarur families, that finances automobile sales to retail customers. Forum Financial Services was later acquired in 2015 by Banco BBVA, Spain’s second-largest bank. Mr. Avayu is active in education through Grupo Cpech, of which he is chairman of the board, manages nonprofit K-12 schools and a technical institute, and offers preparation class for SAT exams to enter higher education. In addition, Mr. Avayu serves on the board of directors of Fobeju Foundation, that provides scholarships to the Hebrew Academy in Chile. He also held the office of president of the Chilean branch of Keren Hayesod – United Israel Appeal for 11 years and continues his affiliation a board member of the fundraising organization.

William O'Neill

Former partner in the corporate finance and M&A practice of Latham & Watkins LLP

MORE ⤑
Recently retired as a partner in the corporate finance and M&A practice of Latham & Watkins LLP in Washington, D.C. Mr. O’Neill has more than 42 years of experience representing public companies and their boards of directors in strategic and transformative transactions. Mr. O’Neill has counseled Hemanext Board since 2005.

Paul M. Ness, M.D.

Senior Director of the Transfusion Medicine Division and Professor of Pathology, Medicine, and Oncology at the Johns Hopkins University School of Medicine

MORE ⤑

Dr. Ness served as Division Director from 1979-2018. From 1983-2000 he directed the Baltimore division of American Red Cross Blood Services leading the Baltimore community through the transfusion issues with the AIDS epidemic. At Johns Hopkins he helped to develop programs in patient blood management, bloodless medicine, therapeutic apheresis, and advanced immunohematology. Prior to coming to Hopkins, he was an undergraduate at MIT, a medical student at SUNY Buffalo, a medical resident at Hopkins, a staff associate in the blood program at NIH, and a hematology –transfusion medicine fellow at UC San Francisco

Dr. Ness was a member of the AABB Board of Directors for many years and became President in 1999. He served as editor of Transfusion from 2003-2018. Dr. Ness has written over 250 articles for medical journals and three texts. Dr. Ness also has extensive experience in transfusion related research with emphasis upon transfusion complications including transfusion transmitted infections and immune destruction of transfused cells. He was a member of the FDA Blood Products Advisory Committee and is currently a member of the Health and Human Services Advisory Committee of Blood and Tissue Safety and Availability.

He served as PI for the Johns Hopkins site of the Transfusion Medicine Hemostasis Clinical Trial Network, funded by NHLBI. Dr. Ness was co-PI for a project funded by the NHLBI REDS III program to study donor virus epidemiology and blood utilization issues in China. He has served as a consultant to the coordinating centers of REDS II, REDS III, and REDS IV. He continues to serve as a consultant to many companies involved in transfusion medicine supplies and practices.

Ismail Kola, PhD

General Partner at Forepont, Visiting Professor of Medicine at Oxford University and Adjunct Professor at several universities and medical schools in the US, Australia and the UK

MORE ⤑

Prior to Forepont, Ismail held several senior executive positions in the pharmaceutical industry.  He has published 159 papers in top scientific journals which have been cited over 16,000 times and has led teams that have brought numerous major medicines to the market during his 20-year career in the pharmaceutical industry.

Ismail Kola was until 2018 the CSO of UCB, His previous positions were: Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, Schering-Plough Research Institute, and Chief Scientific Officer, Schering Plough Corporation; Senior Vice President Basic Research and Site Head, Rahway, Montreal and Madrid, Merck and Chairman of Merck’s Antibacterial and Antifungal Worldwide Business Strategy Team; and Vice President Research, and Global Head, Genomics and Biotechnology at Pharmacia Corporation.

Prior to his move to Industry, Ismail was Professor of Human Molecular Genetics, Monash University Medical School, and Director of the Research Center for Functional Genomics and Human Disease for 15 years.

He is Chairman of the Board of Directors of Athersys Inc. (ATHX, Nasdaq) and a Director of GPN vaccines (Australia).

CONNECT WITH HEMANEXT TODAY!

We are happy to answer any questions about the company, our technology, or our research. Please fill out the form below and we will connect with you!